Bye Bye Blemish

Bye Bye Blemish is an American skincare brand focused on acne and blemish treatment, built around a signature spot treatment called the Drying Lotion. Its products are manufactured in the United States [4] and span drying lotions, toners, serums and acne patches, positioned at an affordable drugstore price point. The brand remains active, selling through its own direct-to-consumer site alongside mass retailers in the United States and pharmacies abroad.

The company presents itself chiefly as a fast-acting, overnight solution for breakouts. Beauty Bar Philippines, a retailer that carries the line, summarises it as "your answer to a fast-acting, overnight treatment for outbreaks, acne and imperfections" [7]. That single-minded focus on visible, quick results runs through the brand's product range and marketing.

The brand's anchor product is the Original Drying Lotion, a spot treatment applied with a cotton swab and left on overnight. The company describes it as "a fast acting on-the-spot skin revitalizer that helps to calm and balance virtually overnight," crediting active ingredients such as salicylic acid and zinc oxide with exfoliating dead skin and letting drying agents penetrate the pores. The lotion is also sold in Tea Tree and Volcanic Ash variants.

From that starting point the line has widened into a fuller acne-focused range, reformulating around minerals rather than harsh alcohols [7]. It now includes the Witch Hazel and Tea Tree Skin Toner, Vitamin C dark-spot products, exfoliating and cleansing gels, and a more recent line of microneedling acne and dark-spot patches. Across these products the recurring active ingredients are salicylic acid, sulfur and zinc oxide, supported by witch hazel, tea tree, vitamin C, niacinamide and hyaluronic acid.

Bye Bye Blemish is consistently positioned at the drugstore end of the market. It is frequently described as an affordable alternative to higher-priced acne treatments, and is most often compared to Mario Badescu's Drying Lotion, with which it shares a similar sulfur, zinc-oxide, salicylic-acid, alcohol and camphor formula at a lower price [10]. The company states that its products are "100% cruelty-free, never tested on animals and proudly made in the USA" [4].

The Drying Lotion has long carried a reputation as a backstage makeup-artist staple. Retailer material describes it as "long known as 'Hollywood's secret weapon against pimples'" through its widespread use by makeup artists [7], and Amazon listings have marketed it as "THE ORIGINAL Hollywood celebrity skincare secret."

The brand has picked up a small number of awards. It was recognised in the 2017 Teen Vogue Acne Awards and named in Cosmopolitan Philippines' 2018 Best Skincare All-Stars [7].

Bye Bye Blemish's products are owned and labelled by Private Label Skin Care, Inc., identified as the parent company in a 2025 U.S. Food and Drug Administration warning letter [8]. The connection does not appear on the brand's own website, which markets Bye Bye Blemish without reference to a parent firm.

In December 2025 the FDA issued a warning letter to Private Label Skin Care, Inc., citing significant violations of Current Good Manufacturing Practice regulations at the company's Canoga Park, California facility [8]. The letter followed an inspection in June 2025 and described the distribution of adulterated over-the-counter drug products containing elevated impurities, along with failures in quality-control oversight.

"Bye, Bye Blemish" was named among 21 over-the-counter drug products that the company had failed to list in the FDA's electronic Drug Registration and Listing System, which the agency said rendered them misbranded under federal law [8]. The FDA called for corrective actions, including a comprehensive quality-control assessment and remediation plan. The warning letter was also covered by industry trade outlets Happi [11] and the Regulatory Affairs Professionals Society [12].

The brand is active. Its official site carries a 2025 copyright, newer Vitamin C and microneedling-patch products remain in retail rotation [1], and the December 2025 FDA warning letter itself reflects ongoing manufacturing operations. Distribution spans the brand's direct-to-consumer website, mass-market retailers in the United States and pharmacy chains internationally.